Coty's latest quarterly report arrived with news that's causing investors to abandon the stock.Coty (COTY -20.89%) stock is getting crushed in Thursday's trading. The beauty products and fragrance company's share price was down 22.3% as of 2 p.m. ET. amid the backdrop of a 0.4% loss for the S&P 500 (^GSPC -0.32%).After the market closed yesterday, Coty published results for the fourth quarter of its last fiscal year, which ended June 30. While the company posted sales that topped Wall Street's expectations, ...

Core Insights - B&G Foods, Inc. reported second-quarter fiscal 2025 results with both net sales and earnings missing the Zacks Consensus Estimate, indicating year-over-year declines in both metrics [1][11] - The company anticipates sequential improvement in the second half of 2025, driven by ongoing portfolio reshaping and recent brand divestitures aimed at enhancing margins and cash flow [1] Financial Performance - Adjusted earnings were 4 cents per share, missing the Zacks Consensus Estimate of 7 cents, and down 50% from 8 cents in the prior-year quarter [2][11] - Net sales decreased 4.5% year over year to $424.4 million, falling short of the Zacks Consensus Estimate of $429 million, attributed to lower volumes, reduced net pricing, and unfavorable product mix [3][11] - Adjusted gross profit was $89.1 million, down from $93.2 million in the year-ago period, with the adjusted gross margin remaining unchanged at 21% [4] - SG&A expenses rose 9.4% to $47.2 million, influenced by higher consumer marketing costs and acquisition/divestiture-related expenses, partially offset by lower warehousing and selling expenses [5] - Adjusted EBITDA fell 9.3% to $58 million, with the adjusted EBITDA margin decreasing to 13.7% from 14.4% in the second quarter of fiscal 2024 [6] Segment Performance - Specialty segment net sales were $134.9 million, down 8% year over year, while adjusted EBITDA increased 3% to $32.7 million due to lower raw material costs [7] - Meals segment net sales were $104.1 million, down 3.5% year over year, with adjusted EBITDA rising 7.7% to $25.7 million, benefiting from improved pricing [8] - Frozen & Vegetables segment net sales were $89 million, down 2.8% year over year, resulting in an adjusted EBITDA loss of $2.7 million compared to a profit of $3.8 million in the prior year [9] - Spices & Flavor Solutions segment net sales were $96.5 million, down 2% year over year, with adjusted EBITDA declining 12.8% to $24.1 million due to higher raw material costs [10] Financial Health - As of the end of the quarter, B&G Foods had cash and cash equivalents of $54.1 million, net long-term debt of $1,984.9 million, and total shareholders' equity of $501.4 million [12] - Net cash provided by operating activities for the fiscal second quarter was $17.8 million [12] Outlook - For fiscal 2025, management revised net sales guidance to a range of $1.830 billion to $1.880 billion, down from the previous estimate of $1.860 billion to $1.910 billion [13] - Adjusted EBITDA is now expected to be between $273 million and $283 million, lower than the previous outlook of $280 million to $290 million [13] - Adjusted EPS guidance for fiscal 2025 was revised to a range of 50-60 cents, down from 55-65 cents, compared to 70 cents per share in fiscal 2024 [14]

Core Insights - Northern Oil and Gas (NOG) reported second-quarter 2025 adjusted earnings per share of $1.37, exceeding the Zacks Consensus Estimate of 87 cents, driven by strong production despite a decline from the previous year's adjusted profit of $1.46 due to lower oil prices and increased operating expenses [1][9] Financial Performance - Quarterly sales reached $574.4 million, surpassing the Zacks Consensus Estimate of $519 million and increasing from $561 million year-over-year, primarily due to higher net gains on commodity derivatives and increased oil and gas sales [2] - Total operating expenses rose to $530.6 million from $341.8 million in the prior year, driven by increased production expenses and other costs, exceeding the estimate of $377.1 million [9] - Free cash flow for the quarter was $126.2 million, with cash on hand at $25.9 million and long-term debt of $2.4 billion [11][14] Production and Sales - Second-quarter production increased 9% year-over-year to 134,094 barrels of oil equivalent per day (Boe/d), beating the estimate of 133,600 Boe/d [7] - Oil volume totaled 76,944 Boe/d, up 10% year-over-year, while natural gas production reached 342,900 thousand cubic feet per day, up 6% [7] - The average sales price for crude was $58.37 per barrel, a 24% decrease from the prior year, while the average realized natural gas price was $2.89 per thousand cubic feet, compared to $2.47 in the previous year [8] Capital Expenditures and Acquisitions - Capital expenditures for the second quarter totaled $210 million, with $178.8 million allocated to drilling and completion activities and $31.2 million for Ground Game efforts [12] - The company completed 22 Ground Game transactions, adding approximately 2,600 net acres and 4.8 net wells for a total of $31.2 million [6][13] - NOG finalized the acquisition of assets in Upton County, TX, for $61.7 million, adding approximately 2,275 net acres to its portfolio [5] Dividend and Share Repurchase - The board declared a cash dividend of 45 cents per share, a 7% year-over-year increase, to be distributed on October 31, 2025 [3] - The company repurchased approximately 1.1 million shares at an average price of $31.15 per share during the second quarter [4] Guidance and Future Outlook - NOG anticipates total capital expenditures for 2025 to be between $925 million and $1.05 billion, reflecting a reduction due to decreased activity in the Williston Basin [15] - Production guidance has been adjusted, with oil production expected in the range of 74,000-76,000 barrels per day and total production at 130,000-133,000 Boe/d [16] - The company expects net cash proceeds of $48.6 million in Q3 after legal settlement deductions of $33.1 million [18]

Company Overview - Westlake Corporation manufactures and markets performance and essential materials, as well as housing and infrastructure products globally, including ethylene, polyethylene, PVC, and vinyl intermediates [1] - Founded in 1986 and headquartered in Houston, Texas, the company also provides consumer and commercial products such as landscape edging and marine dock edging, serving various markets [2] Current Challenges - The company faces challenges from elevated interest rates and lingering inflation, which have dampened housing starts and reduced demand, negatively impacting business confidence [3] - Sluggish construction activity in North America is a concern, particularly affecting the pipe-and-fitting and siding-and-trim businesses [3] Industry Performance - Westlake is a component of the Zacks Chemical – Plastic industry group, which ranks in the bottom 4% out of approximately 250 Zacks Ranked Industries, indicating expected underperformance over the next 3 to 6 months [4] - Stocks in this industry are relatively overvalued and projected to experience below-average earnings growth, with a PE ratio of 92.19 compared to the iShares-SP500's 19.59 [6][7] Stock Performance - WLK shares have been underperforming, hitting a series of lower lows and representing a compelling short opportunity as 2025 approaches [8] - The company has missed earnings estimates in three of the past four quarters, with a significant loss of -$0.31 per share in Q1, missing the Zacks Consensus Estimate by -144.3% [9] - The trailing four-quarter average earnings miss stands at -61.4%, indicating a trend of underperformance [9] Earnings Outlook - Analysts have revised second-quarter earnings estimates down by -88.89% in the past 60 days, with the current Zacks Consensus EPS Estimate at $0.06 per share, reflecting negative growth of -97.5% year-over-year [10] - Falling earnings estimates are viewed as a significant red flag, contributing to a bearish outlook [11] Technical Analysis - WLK stock is in a sustained downtrend, trading below a downward-sloping 200-day moving average, which is a bearish indicator [12] - The stock has experienced a "death cross," where the 50-day moving average crosses below the 200-day moving average, indicating a need for a substantial upside move to warrant long positions [14][15] Conclusion - The combination of a deteriorating fundamental and technical backdrop suggests that WLK is unlikely to reach new highs soon, with a history of earnings misses and falling future earnings estimates likely capping any potential rallies [16] - The stock is recommended to be avoided by potential investors or considered for short or hedge strategies until significant improvements are observed [17]

Core Insights - Dow Inc. is facing significant challenges due to uncertainty around tariffs and difficult industry conditions, leading to a 50% cut in its quarterly dividend [1][4][8] Financial Performance - In Q2 2025, Dow reported a loss of $0.42 per share, missing the Zacks Consensus by $0.31, which represents a miss of 282% [2][8] - Net sales decreased by 7% year-over-year to $10.1 billion, with declines across all operating segments, and a sequential decline of 3% [2][3] - Volumes fell by 1%, with gains in the US and Canada offset by declines in India, the Middle East, Africa, and Europe [3] - Cash from operating activities was negative $470 million, down $1.3 billion year-over-year due to lower earnings from margin compression [3] Dividend and Shareholder Returns - The Board of Directors declared a quarterly dividend of $0.35 per share, a reduction of 50% in response to the prolonged industry downturn, which would yield 5.5% annually if maintained [4][5] - This marks the 456th consecutive dividend payment since 1912, showcasing a long-standing commitment to returning value to shareholders [5] Analyst Sentiment - Analysts have become increasingly bearish on Dow's prospects for 2025 and 2026, with earnings estimates cut significantly [6] - The Zacks Consensus for 2025 earnings has been revised down to $0.24 from $0.38, indicating an 86% decline compared to the previous year's earnings of $1.71 [6] Stock Performance - Dow's shares have reached 1-year and 5-year lows, reflecting ongoing investor concerns amid the challenging macroeconomic environment [8][10] - The stock is not considered cheap, trading at a forward P/E of 107 and a PEG ratio of 11.3, indicating a lack of value based on traditional metrics [12]

Core Insights - Centene Corporation (CNC) reported a second-quarter 2025 adjusted loss per share of 16 cents, missing the Zacks Consensus Estimate of earnings of 68 cents, and a significant decline from the year-ago profit of $2.42 per share [1][11] Financial Performance - The company's revenues increased by 22.4% year over year to $48.7 billion, surpassing the consensus mark by 10.9% [2][11] - Medicaid revenues grew 7% year over year to $21.7 billion, while Medicare revenues surged 58% year over year to $9.5 billion [3] - Commercial revenues improved 18% year over year to $10.1 billion [3] - Total premiums reached $41.7 billion, an 18.8% year-over-year increase, driven by higher premiums and an expanding membership base [4] Membership and Operational Metrics - Total membership (excluding TRICARE) was 28 million as of June 30, 2025, reflecting an 8.9% year-over-year growth, although there were declines in Medicaid and Medicare memberships [6] - The health benefits ratio deteriorated to 93%, a 540 basis point decline year over year, exceeding the consensus mark of 90.82% [7] Expenses and Losses - Operating expenses totaled $49.2 billion, a 27.4% year-over-year increase, attributed to rising medical costs, premium tax expenses, and administrative costs [7] - Adjusted net loss was recorded at $79 million, contrasting with year-ago earnings of $1.3 billion [8] Cash and Equity Position - As of June 30, 2025, Centene had cash and cash equivalents of $14.5 billion, up from $14.1 billion at the end of 2024 [9] - Total assets increased to $86.4 billion from $82.4 billion at the end of 2024, while long-term debt decreased to $17.6 billion from $18.4 billion [9] Share Repurchase Activity - Centene repurchased common shares worth approximately $432 million in the second quarter of 2025 [12] Peer Comparison - Elevance Health, Inc. reported second-quarter 2025 adjusted EPS of $8.84, missing estimates and showing a 12.6% year-over-year decline [13] - UnitedHealth Group is expected to report a significant year-over-year decline in profits despite a projected 12.8% revenue increase [14]

Core Viewpoint - Canopy Growth's stock has significantly declined following a substantial earnings miss, leading to a recommendation to consider selling the stock [1][5]. Group 1: Earnings Performance - Canopy Growth reported a loss of $1.32 per share for Q4 of fiscal 2025, which was much worse than the anticipated loss of $0.20 per share [1]. - Globally, Canopy's sales fell by 11% in Q4, and for the full year, sales were down 9% [5]. - Free cash flow for Q4 was negative $36.2 million, and for the full year, it was negative $176.6 million [5]. Group 2: Management Commentary - Canopy's management highlighted a 4% year-over-year growth in Canadian sales and a 13% growth in Canadian medical cannabis sales [3]. - CEO Luc Mongeau mentioned efforts to unify global medical cannabis businesses to accelerate growth and profitability [3]. - The company has made improvements in Adjusted EBITDA and cash flow but has not yet achieved positive Adjusted EBITDA or Free Cash Flow [4]. Group 3: Market Sentiment - Investors reacted negatively to the earnings report, indicating a lack of confidence in the company's current trajectory [2]. - Despite some positive metrics, the overall trend in sales growth remains negative, raising concerns about the company's future performance [6].

Core Viewpoint - Clorox Co's fiscal third-quarter earnings and revenue missed estimates, leading to a 2.5% decline in share price to $134.96, with profits of $1.45 per share falling below the $1.71 per share from the same quarter last year [1] Group 1: Earnings and Revenue Performance - Clorox reported fiscal third-quarter earnings of $1.45 per share, which is a decrease from $1.71 per share in the same quarter a year ago [1] - The company's revenue also missed market expectations, contributing to the decline in share price [1] Group 2: Analyst Reactions - Following the earnings report, several analysts reduced their price targets for Clorox, with Morgan Stanley lowering its target from $165 to $150 [1] - Despite the price target reductions, there have been no downgrades, as 16 out of 17 brokerages maintain a "hold" or worse rating on the stock [1] Group 3: Stock Performance and Options Activity - Clorox shares traded as low as $129.74 earlier in the day, with the $130 level providing some support against further losses, similar to trends observed in June and July [2] - Since the beginning of the year, Clorox's stock has decreased by 17% [2] - The options market has seen a significant increase in activity, with Clorox stock experiencing quadruple the typical options volume, particularly with the May 125 put being the most popular [2]

Core Viewpoint - Integra LifeSciences Holdings Corporation reported an earnings miss for Q1 2025, with adjusted EPS of 41 cents, falling short of estimates and showing a significant year-over-year decline of 25.5% [1][2][11] Financial Performance - Total revenues for Q1 2025 increased by 3.7% year over year to $382.7 million, slightly exceeding consensus estimates by 0.1% [3] - Organic revenue declined by 3.5% year over year, indicating challenges in core operations [3][11] - Gross profit decreased by 6% year over year to $194.4 million, with gross margin contracting by 526 basis points to 50.8% due to a 16.2% rise in the cost of goods sold [6] - Selling, general and administrative expenses rose by 9.5% to $181.5 million, while research and development expenses fell by 8.3% to $24.7 million [6] Segment Performance - Revenues in the Codman Specialty Surgical segment rose by 9.4% year over year to $280.7 million, although organic growth was down by 1.1% [4] - Neurosurgery sales within this segment fell by 4.7% organically, attributed to shipping holds [4] - Tissue Technologies revenues totaled $102 million, down 9.3% year over year, with notable declines in Private Label sales due to supply delays [5] Financial Position - At the end of Q1 2025, the company had approximately $239.1 million in cash and cash equivalents, down from $246.4 million at the end of Q4 2024 [8] - Cumulative net cash outflow from operating activities was $11.26 million, contrasting with cash inflows of $15.76 million a year ago [8] Guidance - For 2025, the company reaffirmed its revenue guidance of $1.650-$1.715 billion, indicating growth of 2.4%-6.5% [9] - Adjusted EPS forecast was reduced to a range of $2.19-$2.29 from a previous range of $2.41-$2.51 [9] - For Q2 2025, expected revenues are projected between $390-$400 million, reflecting a decline of 6.8%-4.4% [10] Strategic Insights - Despite the earnings miss, the company reported positive contributions from the Acclarent acquisition and double-digit growth in several product lines [12] - The company is focusing on advancing its Compliance Master Plan, expanding its international portfolio, and enhancing leadership [12]